Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099316 | 0.93 | NPC1 (0.39) | GRM5MEN1MAPTKMT2AENPP2 | |
| SCHEMBL16099626 | 0.85 | FKBP1A (0.41) | GRM5MEN1MAPTKMT2AENPP2 | |
| SCHEMBL16100220 | 0.83 | GRM5 (0.39) | GRM5ENPP2ATXN2F2HDAC6 | |
| SCHEMBL16099477 | 0.81 | POLB (0.35) | GRM5MEN1MAPTKMT2AENPP2 | |
| SCHEMBL16102001 | 0.80 | POLB (0.34) | GRM5MEN1MAPTKMT2AENPP2 | |
| SCHEMBL16100249 | 0.77 | MEN1 (0.37) | MEN1KMT2ACNR1FAAH | |
| SCHEMBL16100207 | 0.77 | ENPP2 (0.38) | GRM5ENPP2CYP4F2CYP4A11KCNH2 | |
| SCHEMBL16102126 | 0.75 | POLB (0.34) | GRM5ENPP2ATXN2F2 | |
| SCHEMBL25412001 | 0.75 | GRM5 (0.46) | GRM5CYP4F2CYP4A11HDAC6 | |
| SCHEMBL2526693 | 0.75 | HDAC6 (0.55) | GRM5MEN1MAPTKMT2AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | GRM5 3340/4885MEN1 4761/4885MAPT 4174/4885 |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | GRM5 1744/4885MEN1 687/4885MAPT 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.